Company: ABBV
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001551152-25-000049
Chunk: 27

Company: AbbVie Inc.
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 1
Chunk 27
---
 of tax— — — — — (29)— (29)Dividends declared— — — — (8,264)— — (8,264)Purchases of treasury stock(7)— (1,350)— — — — (1,350)Stock-based compensation plans and other8 — 35 980 — — — 1,015 Change in noncontrolling interest— — — — — — 2 2 Balance at September 30, 20241,767 $18 $(7,848)$21,160 $(4,964)$(2,334)$39 $6,071 Balance at December 31, 20241,765 $18 $(8,201)$21,333 $(7,900)$(1,925)$39 $3,364 Net earnings attributable to AbbVie Inc.— — — — 2,410 — — 2,410 Other comprehensive income, net of tax— — — — — 351 — 351 Dividends declared— — — — (8,744)— — (8,744)Purchases of treasury stock(5)— (977)— — — — (977)Stock-based compensation plans and other7 — 35 958 — — — 993 Change in noncontrolling interest— — — — — — 4 4 Balance at September 30, 20251,767 $18 $(9,143)$22,291 $(14,234)$(1,574)$43 $(2,599)

The accompanying notes are an integral part of these condensed consolidated financial statements.

2025 Form 10-Q | 4

AbbVie Inc. and SubsidiariesCondensed Consolidated Statements of Cash Flows (unaudited) 

Nine months endedSeptember 30,(in millions) (brackets denote cash outflows)20252024Cash flows from operating activitiesNet earnings$2,418 $4,309 Adjustments to reconcile net earnings to net cash from operating activities:Depreciation559 558 Amortization of intangible assets5,593 5,726 Deferred income taxes